{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:02:28Z","timestamp":1756339348906,"version":"3.44.0"},"reference-count":25,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,8,25]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>Immune checkpoint inhibitors are a class of cancer immunotherapy, with a constellation of side effects that require early recognition and management. We present a patient with metastatic adenocarcinoma started on pembrolizumab a month prior, who was admitted to the hospital for bloody diarrhoea. He underwent flexible sigmoidoscopy with biopsy proven grade 3 immune-mediated diarrhoea and colitis. He developed progressively worsening diarrhoea despite appropriate intravenous corticosteroids therapy, and initiation of corticosteroid-sparing therapy was complicated by discovery of hepatitis B core antibodies indicating a chronic hepatitis B carrier state. We discuss our work-up of new onset haemorrhagic diarrhoea in a patient on immunotherapy for metastatic non-small cell lung cancer, as well as a review of current guidelines for antiviral prophylaxis in these patients.<\/jats:p>","DOI":"10.1136\/bcr-2023-256675","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T13:07:12Z","timestamp":1695733632000},"page":"e256675","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Refractory pembrolizumab immunotherapy-related colitis requiring biological therapy in an inactive HBcAb carrier"],"prefix":"10.1136","volume":"16","author":[{"given":"Nidaa","family":"Rasheed","sequence":"first","affiliation":[{"name":"Internal Medicine, University of California San Francisco, Fresno, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University of California San Francisco Fresno, Fresno, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Maddox","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice","family":"Reyes","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of California San Francisco, Fresno, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"2025082623545231000_16.9.e256675.1","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1001\/jamaoncol.2016.2214","article-title":"Genomics- and transcriptomics-based patient selection for cancer treatment with immune checkpoint inhibitors: a review: a review","volume":"2","author":"Dijkstra","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025082623545231000_16.9.e256675.2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025082623545231000_16.9.e256675.3","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025082623545231000_16.9.e256675.4","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv227"},{"key":"2025082623545231000_16.9.e256675.5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/OP.20.00620","article-title":"Immunotherapy-related colitis: an emerging challenge and a quest for prospective data","volume":"16","author":"Kennedy","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2025082623545231000_16.9.e256675.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.01.033"},{"key":"2025082623545231000_16.9.e256675.7","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-020-0752-z","article-title":"Gastrointestinal and hepatic complications of Immunotherapy: current management and future perspectives","volume":"22","author":"Dougan","year":"2020","journal-title":"Curr Gastroenterol Rep"},{"key":"2025082623545231000_16.9.e256675.8","unstructured":"NIH . Common terminology criteria for adverse events V3.0 (CTCAE). Handydex, 2006."},{"key":"2025082623545231000_16.9.e256675.9","article-title":"Immune-mediated adverse events associated with Ipilimumab Ctla-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica (Cairo)"},{"key":"2025082623545231000_16.9.e256675.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.001"},{"key":"2025082623545231000_16.9.e256675.11","doi-asserted-by":"crossref","DOI":"10.3390\/ph14040367","article-title":"Checkpoint inhibitor-induced colitis-a clinical overview of incidence, prognostic implications and extension of current treatment options","volume":"14","author":"Portenkirchner","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025082623545231000_16.9.e256675.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.8506"},{"key":"2025082623545231000_16.9.e256675.13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629"},{"key":"2025082623545231000_16.9.e256675.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1283"},{"key":"2025082623545231000_16.9.e256675.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725"},{"key":"2025082623545231000_16.9.e256675.16","unstructured":"Livertox: clinical and research information on drug-induced liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012."},{"key":"2025082623545231000_16.9.e256675.17","doi-asserted-by":"crossref","unstructured":"Loftus EV , Colombel J-F , Feagan BG , et al . Long-term efficacy of vedolizumab for ulcerative colitis. ECCOJC 2016:jjw177. doi:10.1093\/ecco-jcc\/jjw177","DOI":"10.1093\/ecco-jcc\/jjw177"},{"key":"2025082623545231000_16.9.e256675.18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.20130","article-title":"Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative\/anti-hepatitis B core antigen positive) with rheumatic diseases","volume":"62","author":"Caporali","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025082623545231000_16.9.e256675.19","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S1590-8658(10)60691-3","article-title":"Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease","volume":"43 Suppl 1","author":"Morisco","year":"2011","journal-title":"Dig Liver Dis"},{"key":"2025082623545231000_16.9.e256675.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184550","article-title":"Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-Hbc-positive patients with rituximab-based regimens to treat hematologic malignancies: the preblin study","volume":"12","author":"Buti","year":"2017","journal-title":"PLoS One"},{"key":"2025082623545231000_16.9.e256675.21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"2025082623545231000_16.9.e256675.22","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol Int"},{"key":"2025082623545231000_16.9.e256675.23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.039"},{"key":"2025082623545231000_16.9.e256675.24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/rheumatology\/key298","article-title":"The British society for rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025082623545231000_16.9.e256675.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-256675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:55:08Z","timestamp":1756277708000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-256675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,26]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/bcr-2023-256675"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-256675","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}